P-122 - FACTORS THAT INFLUENCE URINARY INCONTINENCE CORRECTION AFTER PROSTATECTOMY AND RADIOTHERAPY.
P-125 - FEASIBILITY OF MULTIDISCIPLINARY TRANSLATIONAL CAPPRICE PROJECT: STUDY PROTOCOL AND WORKFLOW
P-135 - FUNCTIONAL IMPAIRMENT ON PROSTATE CANCER SURVIVORS ONE YEAR AFTER RADIOTHERAPY
P-146 - HELICAL-TOMOTHERAPY WITH SIMULTANEOUS INTEGRATED BOOST FOR LYMPH NODE-POSITIVE PROSTATE CANCER
P-158 - HYPOFRACTIONATED RADIOTHERAPY FOR INTERMEDIATE PROSTATE CANCER: 5 YEARS OUTCOMES
P-165 - HYPOFRACTIONATION AND VMAT IN PROSTATE CANCER. OUR EXPERIENCE
P-189 - INITIAL EXPERIENCE WITH APALUTAMIDE IN METASTATIC HORMONO-SENSITIVE PROSTATE CANCER (MHSPC)
P-190 - INITIAL EXPERIENCE WITH DAROLUTAMIDE IN NON-METASTATIC PROSTATE CANCER (CPRCM0)
P-191 - INITIAL RESULTS OF APALUTAMIDE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
P-206 - LOCAL RADIOTHERAPY IN METASTATIC HORMONO-SENSITIVE PROSTATE CANCER
P-207 - LOCAL RELAPSE IN MULTIMODAL BLADDER CANCER TREATMENT: MAIN RISK FACTORS
P-215 - LOW-RISK AND FAVORABLE INTERMEDIATE-RISK PROSTATE CANCER: SBRT TOXICITY AND EFFICACY.
P-219 - MAGNETIC RESONANCE-GUIDED RADIOTHERAPY WORKFLOW
P-224 - MINIMALLY INVASIVE GUIDANCE SYSTEM FOR PROSTATIC SBRT
P-228 - MODERATELY HYPOFRACTIONATED RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER WITHOUT IGRT
P-232 - MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING: STAGING IN LOCALIZED PROSTATE CANCER
P-246 - ORGAN-PRESERVATION WITH CONCURRENT IMMUNOTHERAPY AND RADIOTHERAPY IN BLADDER CANCER
P-247 - OUR EXPERIENCE IN PROSTATE SBRT: DVH OPTIMIZATION AND ANALYSIS
P-251 - OUTCOMES EIGHT YEARS LATER RADIOTHERAPY WITH FIDUCIALS IN PROSTATE CANCER
P-259 - PATIENT’S PROFILE WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH APALUTAMIDE
P-268 - PET/TC-PSMA EN EL TRATAMIENTO DE RESCATE DEL CÁNCER DE PRÓSTATA